Tiziana is seeking FDA clearance for a Phase 2 clinical trial testing the safety and efficacy of its foralumab nasal spray in ...
Kim et al. measured cognitive functions related to the frontal and temporal lobes in 16 patients with early-stage ALS stratified by their vital capacity. Patients with reduced vital capacity ...
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback